AC
FDMT icon

Armistice Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

Armistice Capital’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.6M Buy
2,000,000
+64,000
+3% +$557K 0.33% 61
2025
Q4 		$14.5M Buy
1,936,000
+840,000
+77% +$8.52M 0.17% 89
2025
Q3 		$9.52M Buy
1,096,000
+796,000
+265% +$4.76M 0.14% 88
2025
Q2 		$1.11M Hold
300,000
– – 0.02% 146
2025
Q1 		$969K Hold
300,000
– – 0.01% 167
2024
Q4 		$1.67M Sell
300,000
-36,000
-11% -$283K 0.02% 159
2024
Q3 		$3.63M Buy
+336,000
New +$5.58M 0.06% 137

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Armistice Capital's FDMT Position: Q1 2026 in Review

Armistice Capital increased its 4D Molecular Therapeutics (FDMT) stake by 3.3% in Q1 2026, buying an estimated $557K and bringing the position to 2,000,000 shares worth $18.6M. The position accounts for 0.33% of the portfolio, ranked #61.

Armistice Capital first reported a position in FDMT in Q3 2024 and has held it in 7 quarters since. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Armistice Capital held 2,000,000 shares of 4D Molecular Therapeutics worth $18.6M as of Q1 2026.
  • Armistice Capital bought 64,000 4D Molecular Therapeutics shares in Q1 2026, an estimated $557K.
  • 4D Molecular Therapeutics made up 0.33% of Armistice Capital's portfolio in Q1 2026, its #61 holding.
  • Armistice Capital first reported a position in 4D Molecular Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.